Phase 1a First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs Tyzivumab (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- Sponsors Tychan
- 29 Oct 2018 Status changed from active, no longer recruiting to completed, according to a WuXi Biologics media release.
- 29 Oct 2018 Results presented in the Tychan media release.
- 07 Sep 2018 Planned primary completion date changed from 30 Sep 2018 to 30 Oct 2018.